Brief: Intensity Therapeutics: INVINCIBLE-4 TNBC Trial Update
10/09/2025 12:54
Sept 10 (Reuters) - Intensity Therapeutics Inc INTS.O: INTENSITY THERAPEUTICS REPORTS INVINCIBLE-4, PRESURGICAL TRIPLE-NEGATIVE BREAST CANCER STUDY UPDATE INTENSITY THERAPEUTICS INC - PATHOLOGICAL COMPLETE RESPONSE OBSERVED IN FIRST PATIENT OF COHORT A INTENSITY THERAPEUTICS INC - LOCALIZED SKIN IRRITATION OBSERVED, NEW PATIENT ENROLLMENT PAUSED INTENSITY THERAPEUTICS INC - SIGNIFICANT NECROSIS OBSERVED AFTER TWO DOSES OF INT230-6 INTENSITY THERAPEUTICS INC - SAFETY LOOKS FAVORABLE IN COHORT A INTENSITY THERAPEUTICS INC - EXPECT TO REINITIATE ENROLLMENT WITH MODIFIED INT230-6 DOSING REGIMEN AS SOON AS POSSIBLE Source text: ID:nPn8Vck0ra Further company coverage: INTS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing